Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals Ltd, is one of the leading developers and manufacturers of select high-value Active Pharmaceutical Ingredients. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
Financial Results:
Glenmark Life Sciences Ltd reported Revenues for Q4FY24 of ₹537.00 Crores down from ₹621.00 Crore year on year, a fall of 13.53%.
Total Expenses for Q4FY24 of ₹410.00 Crores down from ₹427.00 Crores year on year, a fall of 3.98%.
Consolidated Net Profit of ₹98.00 Crores down 32.88% from ₹146.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹7.99, down 33.14% from ₹11.95 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.